Information Provided By:
Fly News Breaks for April 26, 2016
SRPT
Apr 26, 2016 | 14:28 EDT
WBB Securities analyst Stephen Brozak believes that the mixed panel voting at the AdComm for Sarepta's eteplirsen, especially on the final question, and the urging of CDER director Janet Woodcock to take into account the totality of the data, including patient testimony, leaves a "good chance" that the FDA will ultimately grant conditional approval to the drug and demand a post-approval trial. WBB is reiterating its Strong Buy rating and $40 price target on Sarepta shares, which are down 25% to $11.20 in afternoon trading.
News For SRPT From the Last 2 Days
There are no results for your query SRPT